Opens in a new tab

Anumana Receives First and Only FDA Clearance for ECG-AI Cardiac Amyloidosis Algorithm Using a Standard 12-Lead ECG

Published Scientific Evidence

Category: (Low Ejection Fraction)

Anumana’s ECG-AI® technology is supported by one of the most extensive evidence bases in cardiovascular AI. This library provides direct access to our peer-reviewed validation studies and broader body of clinical research.

February
27
2019
{post_date: F d, Y}
Journal of Cardiovascular Electrophysiology

Prospective Validation of a Deep Learning Electrocardiogram Algorithm for the Detection of Left Ventricular Systolic Dysfunction

Patients undergoing routine ECG may have undetected left ventricular (LV) dysfunction that warrants further echocardiographic assessment. However, identification of these patients can be challenging. We applied the algorithm to all…
January
07
2019
{post_date: F d, Y}
Nature Medicine

Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram

Asymptomatic left ventricular dysfunction (ALVD) is present in 3–6% of the general population, is associated with reduced quality of life and longevity, and is treatable when found,,,. An inexpensive, noninvasive…
February
28
2018
{post_date: F d, Y}
Journal of the Americal College of Cardiology (JACC) / ACC.18

Application Of Artificial Intelligence To The Standard 12 Lead Ecg To Identify People With Left Ventricular Dysfunction

Asymptomatic left ventricular dysfunction (ALVD) is present in 2-9% of the population, is associated with reduced longevity and is treatable when found. Inexpensive, reliable, in office screening is not available.…